Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ORAI1 | Q96D31 | 1/20 | 0.37 |
| ▸ | ORAI2 | Q96SN7 | 1/20 | 0.37 |
| ▸ | ORAI3 | Q9BRQ5 | 1/20 | 0.37 |
| ▸ | TRPV6 | Q9H1D0 | 1/20 | 0.37 |
| ▸ | APLNR | P35414 | 1/20 | 0.33 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.30 |
| ▸ | GRM5 | P41594 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29681228 | 1.00 | ORAI1 (0.37) | ORAI1ORAI2ORAI3TRPV6APLNR | |
| SCHEMBL29954840 | 0.73 | ENPP2 (0.40) | RAB9A | |
| SCHEMBL10092631 | 0.73 | ENPP2 (0.40) | — | |
| SCHEMBL12004168 | 0.71 | ALDH1A1 (0.43) | RAB9A | |
| SCHEMBL200776 | 0.71 | CCR1 (0.48) | ORAI1ORAI2ORAI3TRPV6CYP19A1 | |
| SCHEMBL29956057 | 0.71 | ADRA2A (0.42) | RAB9A | |
| SCHEMBL28375630 | 0.71 | ADRA2A (0.42) | RAB9A | |
| SCHEMBL2210203 | 0.71 | L3MBTL1 (0.45) | RAB9A | |
| SCHEMBL29958138 | 0.71 | CCR1 (0.48) | ORAI1ORAI2ORAI3TRPV6CYP19A1 | |
| SCHEMBL551486 | 0.71 | MGLL (0.48) | ORAI1ORAI2ORAI3TRPV6CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 117 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026090477-A1 | HELICASE INHIBITORS AND USES THEREOF | KIMIA THERAPEUTICS, INC. (US) | 2026-04-30 | — | — | WO | disclosed |
| US-20260069602-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | ACONCAGUA BIO INC (US) | 2026-03-12 | — | — | US | disclosed |
| EP-4594318-A1 | AKT1 MODULATORS | Alterome Therapeutics, Inc. (US) | 2025-08-06 | — | — | EP | disclosed |
| US-20250092040-A1 | AKT1 MODULATORS | ALTEROME THERAPEUTICS, INC. | 2025-03-20 | — | — | US | disclosed |
| US-12239643-B2 | Therapeutic agent for inflammatory diseases, autoimmune diseases, fibrotic diseases, and cancer diseases | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2025-03-04 | — | — | US | disclosed |
| US-20240352023-A1 | IMIDAZOPYRIMIDINE AND IMIDAZOTRIAZINE DERIVATIVE, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2024-10-24 | — | — | US | disclosed |
| WO-2024208315-A1 | AROMATIC HETEROCYCLIC COMPOUND, AND PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | 中国医药研究开发中心有限公司 | 2024-10-10 | — | — | WO | disclosed |
| US-20240252504-A1 | CANNABINOID RECEPTOR TYPE 2 (CB2) MODULATORS AND USES THEREOF | TEON THERAPEUTICS INC (US) | 2024-08-01 | — | — | US | disclosed |
| US-20240239797-A1 | AKT1 MODULATORS | ALTEROME THERAPEUTICS, INC. | 2024-07-18 | — | — | US | disclosed |
| US-12037338-B2 | Imidazopyrimidine and imidazotriazine derivative, and pharmaceutical composition comprising the same | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2024-07-16 | — | — | US | disclosed |
| EP-2758380-A1 | BENZOIC ACID DERIVATIVES AS EIF4E INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2014-07-30 | — | — | EP | disclosed |
| US-8575160-B2 | Imidazole derivatives as aldosterone synthase inhibitors | NOVARTIS AG (CH) | 2013-11-05 | — | — | US | disclosed |
| US-8575160-B2 | Imidazole derivatives as aldosterone synthase inhibitors | NOVARTIS AG (CH) | 2013-11-05 | — | — | US | disclosed |
| WO-2013079425-A1 | NOVEL 2H-INDAZOLES AS EP2 RECEPTOR ANTAGONISTS | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-06-06 | — | — | WO | disclosed |
| WO-2013066736-A1 | QUINOLINE CARBOXAMIDE AND QUINOLINE CARBONITRILE DERIVATIVES AS mGluR2-NEGATIVE ALLOSTERIC MODULATORS, COMPOSITIONS, AND THEIR USE | MERCK SHARP & DOHME CORP. (US) | 2013-05-10 | — | — | WO | disclosed |
| WO-2013066736-A1 | QUINOLINE CARBOXAMIDE AND QUINOLINE CARBONITRILE DERIVATIVES AS mGluR2-NEGATIVE ALLOSTERIC MODULATORS, COMPOSITIONS, AND THEIR USE | MERCK SHARP & DOHME CORP. (US) | 2013-05-10 | — | — | WO | disclosed |
| WO-2013041468-A1 | BENZOIC ACID DERIVATIVES AS EIF4E INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2013-03-28 | — | — | WO | disclosed |
| US-20130079346-A1 | BENZOIC ACID DERIVATIVES | HOFFMANN-LA ROCHE INC. | 2013-03-28 | — | — | US | disclosed |
| US-20130065893-A1 | IMIDAZOLE DERIVATIVES AS ALDOSTERONE SYNTHASE INHIBITORS | NOVARTIS AG (CH) | 2013-03-14 | — | — | US | disclosed |
| US-20130065893-A1 | IMIDAZOLE DERIVATIVES AS ALDOSTERONE SYNTHASE INHIBITORS | NOVARTIS AG (CH) | 2013-03-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240239797-A1 | AKT1 MODULATORS | AKT1S1, AKT1, AKT2 | ORAI1 4022/4885ORAI2 3009/4885ORAI3 3156/4885 |
| US-20130065893-A1 | IMIDAZOLE DERIVATIVES AS ALDOSTERONE SYNTHASE INHIBITORS | CYP11B1, CYP21A2, CYP11B2 | ORAI1 3131/4885ORAI2 2814/4885ORAI3 1395/4885 |
| US-20240352023-A1 | IMIDAZOPYRIMIDINE AND IMIDAZOTRIAZINE DERIVATIVE, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | GRM5, GRIK5, GRM1 | ORAI1 722/4885ORAI2 2754/4885ORAI3 2697/4885 |
| US-20240252504-A1 | CANNABINOID RECEPTOR TYPE 2 (CB2) MODULATORS AND USES THEREOF | CNR2, CNR1, GPR18 | ORAI1 1533/4885ORAI2 1131/4885ORAI3 2282/4885 |
| US-20250092040-A1 | AKT1 MODULATORS | AKT1S1, AKT1, AKT2 | ORAI1 4022/4885ORAI2 3009/4885ORAI3 3156/4885 |
| US-12037338-B2 | Imidazopyrimidine and imidazotriazine derivative, and pharmaceutical composition comprising the same | GRM5, GRIK5, GRM1 | ORAI1 722/4885ORAI2 2754/4885ORAI3 2697/4885 |
| US-20130079346-A1 | BENZOIC ACID DERIVATIVES | EIF4EBP1, EIF4E, EIF4A2 | ORAI1 4066/4885ORAI2 4478/4885ORAI3 4545/4885 |
| US-20260069602-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | SCTR, SSTR1, NPY1R | ORAI1 1288/4885ORAI2 1996/4885ORAI3 1365/4885 |
| US-12239643-B2 | Therapeutic agent for inflammatory diseases, autoimmune diseases, fibrotic diseases, and cancer diseases | CCR1, SSB, C5 | ORAI1 3588/4885ORAI2 4336/4885ORAI3 4385/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.